Barbayianni, Ilianna
Kanellopoulou, Paraskevi
Fanidis, Dionysios https://orcid.org/0000-0002-4053-2090
Nastos, Dimitris
Ntouskou, Eleftheria-Dimitra
Galaris, Apostolos
Harokopos, Vaggelis
Hatzis, Pantelis https://orcid.org/0000-0001-5002-7728
Tsitoura, Eliza
Homer, Robert https://orcid.org/0000-0002-2055-5885
Kaminski, Naftali https://orcid.org/0000-0001-5917-4601
Antoniou, Katerina M.
Crestani, Bruno
Tzouvelekis, Argyrios
Aidinis, Vassilis https://orcid.org/0000-0001-9531-7729
Funding for this research was provided by:
Hellenic Foundation for Research and Innovation #3565
Article History
Received: 5 February 2023
Accepted: 11 September 2023
First Online: 21 September 2023
Competing interests
: A.T. has received fees for speaking and/or organizing education from AstraZeneca, Menarini, Boehringer Ingelheim, Chiesi, Hoffmann-La Roche, Ltd., GlaxoSmithKline and Elpen, for consulting from Boehringer Ingelheim, Pfizer, Gilead, Hoffmann-La Roche, Ltd., GlaxoSmithKline, and has received research funding, including institutional funding, from Boehringer Ingelheim, Chiesi, Hoffmann-La Roche, Ltd., GlaxoSmithKline and Astra Zeneca, outside the submitted work. B.C. has received fees for speaking and/or organizing education from Apellis, Astra Zeneca, BMS, Boehringer Ingelheim, Novartis, Roche and Sanofi, for consulting fees from Apellis, BMS, Boehringer Ingelheim and Sanofi, and has received research funding from Boehringer Ingelheim, outside the submitted work. N.K. is a scientific founder at Thyron, served as a consultant to Biogen Idec, Boehringer Ingelheim, Third Rock, Pliant, Samumed, NuMedii, Theravance, LifeMax, Three Lake Partners, Optikira, Astra Zeneca, RohBar, Veracyte, Augmanity, CSL Behring, Galapagos and Thyron over the last 3 years, reports Equity in Pliant and Thyron, and grants from Veracyte, Boehringer Ingelheim, BMS and non-financial support from MiRagen and Astra Zeneca, outside the submitted work. Other authors declare that they have no conflict of interest.